WallStSmart

Coca-Cola Femsa SAB de CV ADR (KOF)vsArcadia Biosciences Inc (RKDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola Femsa SAB de CV ADR generates 6147748% more annual revenue ($292.51B vs $4.76M). KOF leads profitability with a 7.9% profit margin vs -195.9%. KOF earns a higher WallStSmart Score of 50/100 (C-).

KOF

Buy

50

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.49

RKDA

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.3
Piotroski: 3/9Altman Z: -62.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

KOFUndervalued (+50.9%)

Margin of Safety

+50.9%

Fair Value

$229.42

Current Price

$106.47

$122.95 discount

UndervaluedFair: $229.42Overvalued
RKDAUndervalued (+37.9%)

Margin of Safety

+37.9%

Fair Value

$2.80

Current Price

$1.03

$1.77 discount

UndervaluedFair: $2.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KOF3 strengths · Avg: 8.7/10
Return on EquityProfitability
208.3%10/10

Every $100 of equity generates 208 in profit

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$7.63B8/10

Generating 7.6B in free cash flow

RKDA2 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
28.5%8/10

Earnings expanding 28.5% YoY

Areas to Watch

KOF4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.1%4/10

1.1% revenue growth

Profit MarginProfitability
7.9%3/10

7.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
22.882/10

Expensive relative to growth rate

RKDA4 concerns · Avg: 2.5/10
Market CapQuality
$1.94M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-323.1%2/10

ROE of -323.1% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : KOF

The strongest argument for KOF centers on Return on Equity, Price/Book, Free Cash Flow.

Bull Case : RKDA

The strongest argument for RKDA centers on Price/Book, EPS Growth.

Bear Case : KOF

The primary concerns for KOF are Revenue Growth, Profit Margin, Piotroski F-Score.

Bear Case : RKDA

The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

KOF profiles as a value stock while RKDA is a turnaround play — different risk/reward profiles.

KOF carries more volatility with a beta of 0.53 — expect wider price swings.

KOF is growing revenue faster at 1.1% — sustainability is the question.

KOF generates stronger free cash flow (7.6B), providing more financial flexibility.

Bottom Line

KOF scores higher overall (50/100 vs 38/100). RKDA offers better value entry with a 37.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola Femsa SAB de CV ADR

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola FEMSA, SAB de CV, a franchise bottler, produces, markets, sells and distributes Coca-Cola brand beverages. The company is headquartered in Mexico City, Mexico.

Visit Website →

Arcadia Biosciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.

Visit Website →

Want to dig deeper into these stocks?